samedan logo
 
 
 
spacer
home > ebr > winter 2001 > real options evaluation in pharmaceutical r&d: a new approach to financial project evaluation
PUBLICATIONS
European Biopharmaceutical Review

Real Options Evaluation in Pharmaceutical R&D: A New Approach to Financial Project Evaluation

The financial literature relating to options is daunting, both because of its volume and, in large part, its technical nature - the latter only rendered more obscure by the associated jargon. For those courageous enough to wade into the depths of this literature, frustration will be experienced both in extracting information relevant to pharmaceutical R&D and, even more so, in applying it. Thus, Dr Kerstin M. Bode-Greuel (the author of this report) is unusually well-equipped to act as a guide through the wilderness for the following reasons:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
A Review by Dr Roy Drucker, General Manager at Technomark Consulting Services Ltd

Roy Drucker joined the European R&D arm of Sterling Drug Inc as a Medical Advisor. He was promoted to being responsible for clinical pharmacology, drug metabolism and bioanalysis in Europe. In 1986 he moved to the Upjohn Company, subsequently Pharmacia & Upjohn, Inc., where he held a range of international responsibilities. His positions there included Director of Marketing with responsibility for worldwide marketing of cardiovascular products; Executive Director, European Community Affairs and Business Systems; and Vice-President, Drug Development, with global responsibility in multiple therapeutic areas for clinical drug development and medical support for marketed products.
A graduate of the Harvard Business School Advanced Management Program, Member of the Securities Institute and an FSA registered Approved Person, Roy has been based in Belgium, the UK, and the US. Roy has been General Manager of Technomark since September 1996.

spacer
Roy Drucker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Thermo Fisher Scientific Completes Acquisition of PeproTech, a Leader in Recombinant Proteins

WALTHAM, Mass., Jan. 5, 2022 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, today announced that Thermo Fisher completed its acquisition of PeproTech on December 30, 2021 for a total cash purchase price of approximately $1.85 billion.
More info >>

White Papers

Systems Engineering for Complex Portable Medical Device Development

Phillips-Medisize

As the demand for complex, portable medical devices continues to grow, reducing risk and increasing efficiency during the development of these products should be paramount. Taking a systems-engineering (SE) approach to development provides a holistic, organized, and deliberate method for identifying as well as reducing both patient and business risks early in the process. Furthermore, it facilitates efficient progression throughout the entire product development life cycle.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement